Prosthetic valve endocarditis. The case for prompt valve replacement.
Treatment of patients with prosthetic valve endocarditis with existing guidelines has failed to reduce the over-all mortality rate to below 50 per cent. However, subgroups with high or lower risk of death can be delineated on the basis of risk factors such as early onset following surgery, high-risk causative organisms, cardiodynamic failure, and septic emboli. High-risk patients comprise more than 70 per cent of those with prosthetic valve endocarditis in recent series. Analysis of previously reported series indicates that the mortality rate for high-risk patients with late onset of prosthetic valve endocarditis treated by valve replacement was less than that of patients receiving only medical therapy. We have treated 6 consecutive patients with prosthetic valve endocarditis (3 early onset, 3 late onset) by valve replacement before completion of a course of antibiotics. All patients survived surgery but one patient died after 4 1/2 months of noninfectious causes. Prompt valve replacement is technically feasible and should become the standard therapy for patients with prosthetic valve endocarditis who do not fall into the lower risk group.
D000328:Adult; D001021:Aortic Valve / Q000601:surgery; D002177:Candidiasis / Q000209:etiology; D004697:Endocarditis, Bacterial / Q000209:etiology* / Q000401:mortality / Q000601:surgery; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000209:etiology; D013290:Streptococcal Infections / Q000209:etiology; D014481:United States